Bionexus Gene Lab completes investment in Fidelion Diagnostics

BioNexus Gene Lab (BGLC) announced the completion of its strategic transaction with Fidelion Diagnostics and Tongshu Biotechnology. With the closing of the agreements, BGLC has become a strategic shareholder in Fidelion Diagnostics and secured exclusive commercial rights for the VitaGuard Tumor-Naive Minimal Residual Disease liquid biopsy platform across Southeast Asia. BGLC has acquired a 15% equity position in Fidelion Diagnostics, the company that holds the exclusive global commercial rights to the VitaGuard Tumor-Naive AI-oncology platform. This investment provides BGLC shareholders with direct participation in Fidelion’s international expansion and future capital markets trajectory, including potential private financing rounds or a future “Qualified Financing Event,” which the agreements specifically include listing on Nasdaq or NYSE as options. Simultaneously, BGLC has obtained exclusive, perpetual rights to manufacture, market, and distribute VitaGuard across all ASEAN markets, solidifying the Company as the sole provider of this advanced liquid biopsy technology in one of the world’s fastest-growing oncology regions.